NasdaqCM:AGEN

Stock Analysis Report

Executive Summary

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer.

Snowflake

Fundamentals

Mediocre balance sheet with concerning outlook.

Share Price & News

How has Agenus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.7%

NasdaqCM:AGEN

-0.03%

US Biotechs

-1.0%

US Market


1 Year Return

69.5%

NasdaqCM:AGEN

-8.1%

US Biotechs

-0.4%

US Market

AGEN outperformed the Biotechs industry which returned -8.1% over the past year.

AGEN outperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

AGENIndustryMarket
7 Day9.7%-0.03%-1.0%
30 Day11.9%-0.1%-3.3%
90 Day-4.1%3.1%0.8%
1 Year69.5%69.5%-7.3%-8.1%1.9%-0.4%
3 Year-52.9%-52.9%9.8%6.0%39.4%30.4%
5 Year-7.8%-7.8%8.1%3.1%54.2%37.1%

Price Volatility Vs. Market

How volatile is Agenus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Agenus undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Agenus is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Agenus has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Agenus expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

-2.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Agenus's revenue is expected to grow by 17.9% yearly, however this is not considered high growth (20% yearly).

Agenus is not considered high growth as it is expected to be loss making for the next 1-3 years.

Agenus's revenue growth is expected to exceed the United States of America market average.

Unable to compare Agenus's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Agenus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Agenus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Agenus performed over the past 5 years?

-19.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Agenus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Agenus's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Agenus's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Agenus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Agenus has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Agenus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Agenus's financial position?


Financial Position Analysis

Agenus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Agenus's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Agenus has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Agenus's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Agenus has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Agenus has sufficient cash runway for more than 3 years based on current free cash flow.

Agenus has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -8.1% each year.


Next Steps

Dividend

What is Agenus's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Agenus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Agenus's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Agenus has not reported any payouts.

Unable to verify if Agenus's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Agenus has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Agenus's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Garo Armen (66yo)

25.6yrs

Tenure

US$2,567,842

Compensation

Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...


CEO Compensation Analysis

Garo's remuneration is higher than average for companies of similar size in United States of America.

Garo's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.2yrs

Average Tenure

57yo

Average Age

The average tenure for the Agenus management team is less than 2 years, this suggests a new team.


Board Age and Tenure

10.6yrs

Average Tenure

61yo

Average Age

The average tenure for the Agenus board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Paulo Moreira

    Global Head of Clinical Operations

    • Tenure: 0.4yrs
  • Chris Cortis (51yo)

    Chief Strategy Officer & Head of Finance

    • Tenure: 1.2yrs
  • Don Vidic

    VP & Head of Commercial

    • Tenure: 0.1yrs
  • Jennifer Buell

    Chief Operating Officer

    • Tenure: 0.8yrs
    • Compensation: $986.47k
  • Christine Klaskin (53yo)

    VP of Finance

    • Compensation: $497.48k
  • Evan Kearns

    VP, General Counsel & Secretary

    • Tenure: 1.1yrs
  • Alex Duncan (57yo)

    CTO & Head of Research

    • Tenure: 3.6yrs
    • Compensation: $833.26k
  • Ozer Baysal (63yo)

    Chief Commercial Officer & Head of HR

    • Tenure: 2.1yrs
    • Compensation: $461.73k
  • John Castle

    Head of Translational Medicine & Bioinformatics

    • Tenure: 1.6yrs
  • Garo Armen (66yo)

    Founder

    • Tenure: 25.6yrs
    • Compensation: $2.57m

Board Members

  • Garo Armen (66yo)

    Founder

    • Compensation: $2.57m
  • Ulf Wiinberg (61yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: $195.08k
  • Wadih Jordan (84yo)

    Independent Director

    • Tenure: 16.4yrs
    • Compensation: $113.70k
  • Tim Wright (61yo)

    Lead Director

    • Tenure: 10.6yrs
    • Compensation: $218.70k
  • Brian Corvese (61yo)

    Independent Director

    • Tenure: 12.4yrs
    • Compensation: $257.58k
  • Allison Jeynes-Ellis (53yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: $167.78k

Company Information

Agenus Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Agenus Inc.
  • Ticker: AGEN
  • Exchange: NasdaqCM
  • Founded: 1994
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$388.595m
  • Shares outstanding: 137.31m
  • Website: Click here

Number of Employees


Location

  • Agenus Inc.
  • 3 Forbes Road
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGENNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2000
AJ81DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2000

Biography

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 23:32
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.